Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)
Many patients with pulmonary arterial hypertension do not achieve treatment goals with monotherapy, and therefore combination therapy is becoming the standard of care. The soluble guanylate cyclase stimulator riociguat is licensed for the treatment of pulmonary arterial hypertension; here we present...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-07-01
|
| Series: | Pulmonary Circulation |
| Online Access: | https://doi.org/10.1177/2045894020942121 |